Open up the channel of Shenzhen-Hong Kong cooperation and explore a new development path - Expert teams from Hong Kong Institute of Biotechnology, Fosun Kate and Peking University Shenzhen Hospital vi
Accompanied and explained by Chairman Shi Yuanyuan, the visiting experts visited the smart exhibition hall, production workshop and R&D laboratory of Shenzhen Cell Valley to further understand the company's development history, core team, advantages of retroviral vector used to prepare cell therapy products, four service platforms - virus products, cell products, auxiliary declaration, talent training, GMP level production and construction. Clinical application progress, major technological breakthroughs and enterprise comprehensive strength.
At the symposium, Chairman Shi Yuanyuan extended a warm welcome to the guests and proposed that Shenzhen Cell Valley would join hands with HKIB, Fosun Kate and Peking University Shenzhen Hospital to integrate the superior resources of leading enterprises, medical institutions, scientific research institutes and industrial service infrastructure CRO/CDMO platform. In particular, the special location advantages and supporting policies of Shenzhen and Hong Kong will create a Shenzhen-Hong Kong cooperation demonstration project to co-build innovative cell therapy models and mechanisms between the two places. Dr.Gina Jiang, President of HKIB, introduced that HKIB is currently building the first cell GMP preparation laboratory in Hong Kong entrusted by the Hong Kong Hospital Authority, and it is expected that cell therapy products produced in Hong Kong will be put into clinic in the first half of this year.? Chen Junhui, director of Peking University Shenzhen Hospital, said that the hospital has rich experience in IIT and IND clinical research on hematoma and solid tumor. Dr. Shi Yuanyuan introduced the recent major breakthroughs in the production and preparation of CAR-NK and CAR-γδT cells in Shenzhen Cell Valley, and said that with the support of policy and market demand, cell therapy is a key field of future medicine, Shenzhen Cell Valley is deepening the cooperation between industry, university and research, and is committed to building an open platform to cooperate with outstanding teams and enterprises at home and abroad. Promote the development of cell and gene therapy industry chain.
The participants carried out detailed and in-depth exchanges on the recent research progress and results of cell therapy products, core technologies and advantages, basic and clinical research, and enterprise construction and development, laying a solid foundation for discussing cooperation models and close cooperation in the later stage. All parties agreed to rapidly promote cooperation, strive to open up the industrialization and internationalization of cell therapy in the mainland and Hong Kong, and explore a new development path for China's CGT industry.
